loader image
Saturday, December 20, 2025
84.8 F
McAllen
- Advertisement -

Suing Pfizer for Knowingly Misrepresenting the Efficacy of the COVID-19 Vaccine

Translate to Spanish or other 102 languages!

 Attorney General Ken Paxton has filed a notice of appeal to continue his lawsuit against Pfizer, Inc., for its unlawful misrepresentations concerning the COVID-19 vaccine after a district court dismissed the case. Logo: Public Domain. Bgd for illustration purposes
 Attorney General Ken Paxton has filed a notice of appeal to continue his lawsuit against Pfizer, Inc., for its unlawful misrepresentations concerning the COVID-19 vaccine after a district court dismissed the case. Logo: Public Domain. Bgd for illustration purposes
- Advertisement -

AUSTIN – Attorney General Ken Paxton has filed a notice of appeal to continue his lawsuit against Pfizer, Inc., for its unlawful misrepresentations concerning the COVID-19 vaccine after a district court dismissed the case.

In November 2023, Attorney General Paxton sued Pfizer for unlawfully misrepresenting the effectiveness and safety of the company’s COVID-19 vaccine. Further, Pfizer conspired with social media platforms to censor criticism and label posts containing truthful information about its vaccine as “misinformation.” In December 2024, a federal district judge dismissed the lawsuit, claiming that the federal government had given Pfizer immunity through the Public Readiness and Emergency Act. Today, Attorney General Paxton filed a notice that we will appeal the ruling and continue fighting to hold Pfizer accountable.

“Pfizer repeatedly and knowingly misrepresented the effectiveness and safety of their COVID-19 vaccine and pressured Americans to take the shot without full knowledge of the risks,” said Attorney General Paxton. “When consumers questioned the effectiveness and safety of the vaccine, Pfizer sought to silence them—prioritizing profits over the truth. I will not stop until Pfizer is held accountable for deceptively pushing its COVID-19 vaccine on consumers.”

- Advertisement -

To read the filing, click here.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Heart Association Highlights 2025’s Major Research Findings

In 2025, cardiovascular investigators worldwide reported findings that could help fill important gaps in preventing and managing conditions including high blood pressure, stroke, heart failure, dangerous blood clots and aortic stenosis.

DHR Health and Brownsville Join Forces on Major Hospital Expansion

The City of Brownsville and DHR Health announced a new public-private partnership to expand DHR Health Brownsville, marking a major investment in local healthcare and economic development

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.
- Advertisement -
×